EP1513419A2 - Methode und zusammensetzung zur behandlung oder vorbeugung von abbaureaktionen oder zur stimulierung von aufbaureaktionen in säugetieren, die sich unter stress befinden - Google Patents

Methode und zusammensetzung zur behandlung oder vorbeugung von abbaureaktionen oder zur stimulierung von aufbaureaktionen in säugetieren, die sich unter stress befinden

Info

Publication number
EP1513419A2
EP1513419A2 EP03760968A EP03760968A EP1513419A2 EP 1513419 A2 EP1513419 A2 EP 1513419A2 EP 03760968 A EP03760968 A EP 03760968A EP 03760968 A EP03760968 A EP 03760968A EP 1513419 A2 EP1513419 A2 EP 1513419A2
Authority
EP
European Patent Office
Prior art keywords
methyl
serine
composition
group
acceptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP03760968A
Other languages
English (en)
French (fr)
Inventor
Robert Johan Joseph Hageman
George Verlaan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nutricia NV
Original Assignee
Nutricia NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutricia NV filed Critical Nutricia NV
Priority to EP16199313.4A priority Critical patent/EP3184107A1/de
Priority to EP03760968A priority patent/EP1513419A2/de
Priority to EP20100186325 priority patent/EP2283835A3/de
Publication of EP1513419A2 publication Critical patent/EP1513419A2/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the invention relates to a method of treating or preventing catabolism or of stimulating anabolism in a mammal undergoing metabolic stress. More particularly, the present method is concerned with such a method that comprises administering to the mammal a composition containing methyl donors selected from the group consisting of L-serine, methiomne, phosphatidyl choline, choline, betaine, dimethylglycine, sarcosine, methylated folates, S-adenosyl methionine, thymidine triphosphate, adenosine triphosphate and combinations thereof and optionally methyl acceptors selected from the group consisting of L-glycine, phosphatidyl ethanolamine, ethanolamine, folate, ribose and combinations thereof, wherein the total molar amount of methyl donors delivered by the method exceeds the total molar amount of methyl acceptors delivered by the same method by at least 0.18 mmol per kg of body weight per day.
  • Another aspect of the invention relates to a method for the stimulation and/or increase of anabolic processes and/or the providing of an increase of the lean body mass, and/or prevention and/or treatment of muscle catabolism or even cachexia and/or for the improvement of the energy status of tissues and cells by administering to the mammal a composition containing methyl donors selected from the group consisting of L-serine, methiomne, choline, phosphatidyl choline, betaine, dimethylglycine, sarcosine, methylated folates, S-adenosyl methionine, thymidine triphosphate, adenosine triphosphate and optionally methyl acceptors selected from the group consisting of L-glycine, ethanolamine, phosphatidyl ethanolamine, folate, ribose, wherein the total molar amount of methyl donors delivered by the method exceeds the total molar amount of methyl acceptors delivered by the method by at least
  • Still another aspect of the invention relates to a method for the prevention and/or treatment, in particular prevention of disorders selected from cancer, neurological disorders, migraine, allergy, insulin resistance which improves glucose tolerance and decreases side effects of diabetes type II, cardiovascular and cerebrovascular disorders, hypercholesterolaemia, hypertension, subfertility, uncontrolled inflammation processes, pneumonia, and mixtures thereof, and/or prevention of hearing loss, and/or improvement of wound healing, and/or improvement of gut barrier function and/or prevention of sepsis, by administering to the mammal a composition containing methyl donors selected from the group consisting of L-serine, methiomne, choline, phosphatidyl choline, betaine, dimethylglycine, sarcosine, methylated folates, S- adenosyl methionine, thymidine triphosphate, adenosine triphosphate and optionally methyl acceptors selected from the group consisting of L-glycine, ethanolamine, phosphati
  • a method for increasing the methylation capacity of a subject comprises administering to the mammal a composition containing methyl donor L-serine, and optionally methyl acceptors selected from the group consisting of L-glycine, ethanolamine, phosphatidyl ethanolamine, folate, ribose, wherein the total molar amount of methyl donors delivered by the method exceeds the total molar amount of methyl acceptors delivered by the method by at least 0.18 mmol per kg of body weight per day.
  • Another aspect of the invention relates to a pharmaceutical or nutritional composition containing at least 0.5 mmol of methyl donors per gram of dry matter and between 0.01 and 1000 mol of methyl acceptors per gram of dry matter, wherein the methyl donors and methyl acceptors are contained in the composition in a molar ratio of at least 3:1.
  • a typical nutritional infusion solution comprises an aqueous solution of carbohydrates, fats and amino acids.
  • a typical nutritional formula for enteral use will provide high amounts of protein and much energy per gram of product.
  • such formulae are often ineffective in reversing net catabolism, even though they are sometimes capable of delaying net catabolism to some extent.
  • the high density of nutrients causes several problems, including an adverse effect on taste and product stability. This is particularly important for patients suffering from metabolic stress who, due to their disease, suffer from reduced appetite and who generally are capable of consuming only relatively small amounts of food or drinks.
  • An anabolic response is desired during growth.
  • infants, in particular premature infants need effective nutritional support to achieve rapid weight gain and to increase life expectations.
  • methylation reactions fulfil a critical role in supporting the anabolic processes that are essential in counteracting the catabolic impact of said stress.
  • methylation reactions fulfil a critical role in supporting the anabolic processes that are essential in counteracting the catabolic impact of said stress.
  • a mammal's capability to adequately start up, maintain and support these anabolic processes, and in particular its ability to maintain a positive nitrogen balance is often compromised because its diet does not provide adequate quantities of methylation supporting agents.
  • Methylation reactions are very important biochemical processes that occur in the body of all mammals. Methylation reactions are characterized by the exchange of a moiety that comprises a single carbon atom (one-carbon metabolism), often a methyl radical, between two reactive molecules. For the purpose of this document reactions in which such moiety is transferred from a donor to an acceptor molecule is defined as a methylation reaction and the reverse reaction as a demethylation reaction. Well-known substances involved in methylation reactions include S-adenosyl methionine (SAM) and specific folates.
  • SAM S-adenosyl methionine
  • tetrahydrofolate may be methylated to various folate derivatives, including 5-methyl THF, 5-formyl THF, 10-formyl THF and 10- methylene THF, which are referred to in this document as methylated folates.
  • these methylated folates may participate in methylation reactions as methyl donors by transferring their one carbon moiety (methyl, formyl or methylene radical) to a methyl acceptor.
  • a methyl donor is a substance capable of participating in in vivo methylation reactions by transferring a one carbon moiety to another substance, the methyl acceptor.
  • Methylation reactions play a crucial role in various biosynthesis pathways and interlink many important metabolic processes.
  • critical methylation reactions include the aforementioned methylation of folate, the conversion of glycine to serine and of homocysteine to methionine.
  • Other examples of methylation reactions are the methylation of guanidino acetate to creatine, de novo biosynthesis of nucleotides (purines) and the biosynthesis of carnitine from proteinaceous lysine.
  • An example of a demethylation reaction includes the conversion of betaine into dimethylglycine.
  • Transmethylation pathways closely interconnect choline, methionine, methyl THF and vitamins B6 and B12.
  • the pathways intersect at the formation of methionine from homocysteine. Perturbing the metabolism of one of these pathways results in compensatory changes in the others.
  • methionine can be formed from homocysteine using methyl groups from methyl THF, or using methyl groups from betaine that are derived from choline.
  • methyl-THF can be formed from one- carbon units derived from serine or from methyl groups of betaine.
  • choline can be synthesized de novo using methyl groups derived from methionine (via S-adenosylmethionine).
  • methylation and demethylation reactions are interrelated and that together they ensure that homeostasis of methyl-groups can be maintained. Without wanting to be bound by theory, the inventors believe that methyl- group homeostasis is a dominating factor in creating anabolism or catabolism.
  • a normal human diet provides nutritional components that are capable of providing available methyl groups (methyl donors) as well as components that are capable to act as methyl acceptor in vivo after digestion and first pass metabolism. Depending on the diet, the sum of methyl-donors may exceed the total amount of acceptors. Typically, this excess will be about 30-40 mmol, which meets average daily demands in normal situations.
  • the inventors have found that mammals undergoing metabolic stress have a strongly increased requirement for methyl donors in their diet. If the mammal's diet does not provide an adequate amount of excess methyl donors, anabolic processes will be suppressed or even come to a halt, resulting in a negative nitrogen balance and eventually in a condition of catabolism. The development of such a condition may be prevented by supplying an adequate amount of methyl donors together with sufficient nitrogen source, e.g. by ingesting or administering a nutritional or pharmaceutical preparation. However, the inventors have made the important discovery that the beneficial effect of methyl donors can be offset completely by methyl acceptors present in the same reparation.
  • the net amount of methyl donors is defined in here as the difference between the molar amount of methyl donors and the molar amount of methyl acceptors that is administered.
  • the present invention relates to a method of treating or preventing catabolism or of stimulating anabolism in a mammal undergoing metabolic stress, which method comprises admimstering to the mammal a composition containing methyl donors selected from the group consisting of L-serine, methionine, choline, phosphatidyl choline, betaine, dimethylglycine, sarcosine, methylated folates, S- adenosyl methionine, thymidine, nucleobase or nucleotides and combinations thereof and optionally methyl acceptors selected from the group consisting of L-glycine, ethanolamine, phosphatidyl ethanolamine, folate, ribose and combinations thereof, wherein the total molar amount of methyl donors delivered by the method exceeds the total molar amount of methyl acceptors delivered by the method by at least 0.18 mmol per kg of body weight per day.
  • methyl donors selected from the group consisting of L-
  • the total molar amount of methyl donors delivered by the present method exceeds the total molar amount of methyl acceptors by at least 0.22 mmol per kg of body weight per day, more preferably by at least 0.3 mmol per kg of body weight per day and most preferably by at least 0.8 mmol per kg of body weight per day such as more than than 1.0, preferably more than 1.2, most preferably more than 1.5 mmol per kg of body weight per day.
  • methyl donors and “methyl acceptors” not only encompass the representatives specifically mentioned herein, but also pharmaceutically acceptable salts thereof as well as precursors capable of liberating these substances in vivo when used in accordance with the present invention.
  • suitable examples of such precursors include proteins, peptides, glycoproteins, glycopeptides, oligosaccharides and polysaccharides.
  • Polymeric precursors, such as proteins may suitably contain a plurality of methyl donors and/or methyl acceptors. If the present composition contains, for example, 1 mmol of a protein containing 30 residues of a particular methyl donor, the composition is deemed to contain 30 mmol of said methyl donor.
  • folates includes folic acid and salts thereof. It is preferable to use reduced forms of folate such as tetrahydrofolates and folinic acid.
  • folates includes folic acid and salts thereof. It is preferable to use reduced forms of folate such as tetrahydrofolates and folinic
  • methylated folates encompasses methyl folates, formyl folates and methylene folates.
  • the methyl donors are selected from the group consisting of L-serine, methionine, choline, phosphatidyl choline, methylated folates, S-adenosyl methiomne and combinations thereof. Even more preferably, the methyl donors are selected from the group consisting of L-serine, phosphatidyl choline, methylated folates and combinations thereof. Most preferably, the methyl donor is L- serine. L-serine is a particularly powerful methyl donor that can be administered in substantial quantities without significant side effects.
  • the methyl acceptors are selected from an even larger group consisting of L-glycine, homocysteine, ethanolamine, phosphatidyl ethanolamine, folate, uridine triphosphate, guanidino acetate , ribose and combinations thereof.
  • the composition employed in the present method preferably contains at least 0.3 mmol of the methyl donors, up to about 0.8 mmol, per gram of dry matter. More preferably, the composition contains between 0.4 and 0.7 mmol methyl donors per gram of dry matter.
  • the present composition advantageously contains a significant amount of proteinaceous matter as proteinaceous matter is required to restore or maintain a positive nitrogen balance in the mammal. Whenever referred to in here, the term
  • proteinaceous matter encompasses free amino acids, peptides and proteins.
  • the present method employs a composition containing at least 20% proteinaceous matter, preferably at least 40% proteinaceous matter by weight of dry matter, and the method delivers at least 0.5 g proteinaceous matter, preferably at least 0.7 g, more preferably at least 1.0 g proteinaceous matter by kg of body weight per day.
  • the amount of methyl donors contained in the proteinaceous matter of the present composition is at least 0.9 mmol, more preferably at least 1.0 mmol and most preferably at least 1.2 mmol per gram of the proteinaceous matter.
  • methyl donors and methyl acceptors referred to herein are defined with respect to proteinaceous methyl donors and acceptors.
  • serine and methionine are methyl donors and glycine is a methyl acceptor.
  • the other amino acids are considered to be neutral in this respect, although arginine and lysine can act as a methyl acceptor under certain conditions; for the purpose of the present definition however, they are also considered to be neutral.
  • the method preferably comprises administering a source of L-serine in an amount that does not deliver more than 0.01 mmol per kg of body weight per day of a serine-containing methyl donor selected from the group consisting of phosphatidyl serine, conjugated serine derivatives and combinations thereof.
  • the composition is suitably administered orally, intravenously or through enteral feeding.
  • the molar amount of L-glycine, if present in the composition preferably does not exceed 30% of the molar amount of the methyl donors contained therein.
  • the composition contains a significant amount of serine and/or methionine.
  • the composition contains at least 0.1 mmol serine and/or methionine by weight of proteinaceous matter.
  • the present composition advantageously contains a combination of L-serine and methionine, preferably in a molar ratio within the range of 10:1 and 1:10. More preferably, said ratio is within the range of 6:1 and 1:6, most preferably it does not exceed 1 :4.
  • the amount of cysteine contained in the present composition preferably is below 3% by weight of proteinaceous matter.
  • the molar ratio of cysteine to methionine will be less than 4:1, preferably less than 3:1.
  • Metabolic stress is the condition in which the body metabolizes nutrients at a greater rate than the nutrients are supplied to the body, which can result in a state of destructive metabolism, also referred to as catabolism.
  • This state can be induced by illnesses, particularly those illnesses that interfere with normal digestion, e.g. infections of the gastrointestinal tract. Often, this state is caused by surgery which is disruptive of normal metabolism processes. Further the state can be induced by traumas which induce a necessity for high caloric intake. For example, a burn patient may require as many as 7,000 calories per day due to damage to the body and the results thereof occasioned by the burn. Patients suffering from a catabolic state suffer from severe body weight loss which can result in pronounced complications to the primary malady, severe body damage and even death.
  • this form of supplementation is beneficial in individuals who undergo metabolic stress as a result of extreme physical exercise, e.g. in.athletes.
  • this form of supplementation may be used advantageously to support anabolic processes in individuals who experience elevated rates of tissue growth, e.g. in infants or in pregnant and lactating females.
  • the present method may be employed to treat subjects suffering from some form of metabolic stress.
  • subjects that may suitably be treated by means of the present method include patients undergoing radiation therapy or chemotherapy; trauma patients or patients who have undergone surgery; individuals suffering from a dysfunction of the gastrointestinal tract; pregnant or lactating females; infants, especially pre-term infants and athletes; elderly persons especially elderly persons of high age (e.g. over 75) or elderly suffering from sever body weight loss.
  • the method according to the present invention is particularly suitable for treating individuals who suffer from a pronounced form of metabolic stress as evidenced by a normalised urinary nitrogen excretion of at least about 15 g day.
  • a significant fraction of the methyl donors is administered in the form of L-serine as L-serine is a particularly powerful methyl donor.
  • L-serine is a particularly powerful methyl donor.
  • Particularly suitable sources of L-serine include the free amino acid, serine containing peptides and protein and glycosylated derivatives thereof.
  • the method preferably comprises administering at least 0.1 mmol L- serine per kg of body weight per day in the form of one or more sources of L-serine selected from the group consisting of: free L-serine; a L-serine containing oligopeptide comprising between 2 and 5 amino acid residues; glycosylated derivatives of said free L-serine; and glycosylated derivatives of said oligopeptide.
  • sources of L-serine selected from the group consisting of: free L-serine; a L-serine containing oligopeptide comprising between 2 and 5 amino acid residues; glycosylated derivatives of said free L-serine; and glycosylated derivatives of said oligopeptide.
  • the present method comprises the co-administration of vitamins that fulfill an important role as co-enzymes in biological methylation processes, especially folate, vitamin B6 and vitamin B12.
  • the method comprises co-administering at least 12 nmol of folate per kg of body weight per day, which is equivalent to an amount of about 400 ⁇ g per day for an adult.
  • the co-administered amount of vitamin B6 per kg of body weight per day preferably is at least 0.21 ⁇ mol, i.e. at least about 2.5 mg per day per adult.
  • Vitamin B12 is advantageously co-administered in an amount of at least 0.03 nmol per kg of body weight per day or at least about 2.8 ⁇ g per day for an adult.
  • the terms "vitamin B6" and “vitamin B12” encompass precursors capable of delivering these vitamins in vivo when used in accordance with the present method as well as any metabolites of these vitamins that have a similar biological functionality.
  • the present composition has also been found beneficial for other applications, in particular for:
  • pancreas disorders tumors, like those in liver, pancreas lung and kidney, during malnutrition, during several neurological disorders, during lung emphysema and other respiratory diseases, liver disorders like cirrhosis, severe inflammation like during inflammatory bowel disease, pancreatitis, hepatitis, AIDS and during severe insulin resistance as may occur in diabetes;
  • the increase of lean body mass and energy status leads to an increase in muscle strength and power.
  • vegetarians will profit from the invention composition since the presence of creatine is for a majority of vegetarians marginal.
  • a method for the stimulation and/or increase of anabolic processes and/or the providing of an increase of the lean body mass, and/or prevention and/or treatment of muscle catabolism or even cachexia and/or for the improvement of the energy status of tissues and cells by administering to the mammal a composition containing methyl donors selected from the group consisting of L-serine, methionine, choline, phosphatidyl choline, betaine, dimethylglycine, sarcosine, methylated folates, S-adenosyl methionine, thymidine triphosphate, adenosine triphosphate and optionally methyl acceptors selected from the group consisting of L-glycine, ethanolamine, phosphatidyl ethanplamine, folate, ribose, wherein the total molar amount of methyl donors delivered by the method exceeds the total molar amount of methyl acceptors delivered by the
  • the present composition has also been found beneficial for the prevention and/or treatment, in particular prevention of disorders selected from:
  • -cancer especially cancer to liver, kidneys, pancreas, testis, mammae, ovaria and prostate and colon, but also by prevention of the occurrence of hyperproliferation in tissue like gut (polyps), skin (warts) or prostate,
  • Alzheimer's disease or other dementias Parkinson's disease
  • sensitivity to pain depression
  • multiple sclerosis epilepsy
  • -cardiovascular and cerebrovascular disorders such as those described in WO 01/84961, hypercholesterolaemia, hypertension, prevention of hearing loss, -subfertility,
  • methylation power it is meant that the molar amount of methyl donors exceeds the molar amount of methyl acceptors, and preferably the amount of methyl donors minus methyl acceptors exceeds the average requirement for methyl groups per day as per given hereinbefore.
  • a method for the prevention and/or treatment in particular prevention of disorders selected from cancer, neurological disorders, migraine, allergy, insulin resistance which improves glucose tolerance and decreases side effects of diabetes type II, cardiovascular and cerebrovascular disorders, hypercholesterolaemia, hypertension, subfertility, uncontrolled inflammation processes, pneumonia, and mixtures thereof, and/or prevention of hearing loss, and/or improvement of wound healing, and/or improvement of gut barrier function and/or prevention of sepsis, by admimstering to the mammal a composition containing methyl donors selected from the group consisting of L-serine, methionine, choline, phosphatidyl choline, betaine, dimethylglycine, sarcosine, methylated folates, S-adenosyl methionine, thymidine triphosphate, adenosine triphosphate and optionally methyl acceptors selected from the group consisting of L- glycine, ethanolamine
  • a method for increasing the methylation capacity of a subject comprises administering to the mammal a composition containing methyl donor L-serine, and optionally methyl acceptors selected from the group consisting of L-glycine, ethanolamine, phosphatidyl ethanolamine, folate, ribose, wherein the total molar amount of methyl donors delivered by the method exceeds the total molar amount of methyl acceptors delivered by the method by at least 0.18 mmol per kg of body weight per day.
  • Another aspect of the invention relates to a pharmaceutical or nutritional composition containing: a. at least 0.5 mmol of methyl donors per gram of dry matter, said methyl donors being selected from the group consisting of L-serine, methionine, choline, phosphatidyl choline, betaine, dimethylglycine, sarcosine, methylated folates, S-adenosyl methionine, thymidine triphosphate, adenosine triphosphate and combinations thereof; and b.
  • methyl acceptors being selected from the group consisting of L-glycine, ethanolamine, phosphatidyl ethanolamine, folate, ribose and combinations therepf; wherein the methyl donors and methyl acceptors are contained in the composition in a molar ratio of at least 3:1, preferably at least 3.4:1, more preferably at least 3.6:1 or even at least 4.2:1.
  • the composition contains at least 1 mmol, more preferably at least 1.4 mmol, most preferably at least 2 mmol of methyl donors per gram of dry matter.
  • a pharmaceutical or nutritional composition as defined above is particularly suitable for use in a method of treatment as described herein before as it contains a relatively concentrated net amount of methyl donors.
  • methyl donors are present in the composition in a much higher amount than methyl acceptors.
  • the present composition preferably contains methyl donors and methyl acceptors in a ratio of at least 5:1, more preferably of at least 7:1 and most preferably of at least 8:1 or even about 10. In particularly, these ratios can also apply to L-serine being considered as the only methyl donor and L-glycine being considered as the only methyl acceptor.
  • the present composition additionally contains at least 0.8 ⁇ mol of folate.
  • the composition additionally contains at least 15 ⁇ mol of vitamin B6.
  • the composition additionally contains at least 2.2 nmol of vitamin B 12.
  • the present pharmaceutical or nutritional compositions is suited for enteral administration and preferably for oral administration.
  • the composition may be provided in solid, semi-solid or liquid.
  • the present composition may suitably take the form of a (reconstitutable) beverage, a bar, an ice cream, a meal component (e.g. a soup or a dessert) an aqueous fluid for enteral feeding.
  • the present composition is pourable and contains at least 80 wt.% water. Even more preferably, the present composition does not contain solid particles with a size of 1 mm or more.
  • the present composition preferably contains additional nutrients, especially carbohydrates and lipids.
  • the amounts of proteinaceous matter, carbohydrates and lipids contained in the. present composition expressed as energy percentages are within the following ranges: protein 15-100%, carbohydrates 0-60%, lipids (including phospholipids) 0-50%.
  • the present composition is a complete formulation useful for enteral administration containing 15-35 en% of protein, 35-55 en% of carbohydrates and 30-50 en% of lipids.
  • nutritional supplements are part of the invention, which can contain 35-100% of protein, 0-35 en% of carbohydrates and 3- 65 en% of lipids.
  • Liquids for intravenous administration must be sterile and preferably do not contain any undissolved components and allergens like proteins
  • Another aspect of the invention relates to a pharmaceutical or nutritional composition containing:
  • the composition contains at least 0.4 mmol L-serine per gram of dry matter and more preferably between 0.4 and 0.7 mmol L-serine per gram of dry matter as hereinbefore given, hi a preferred embodiment, the proteinaceous matter is comprised of at least 50 wt.% of whey protein.
  • a pharmaceutical or nutritional composition as defined above is particularly suitable for use in a method of treatment as described herein before as it contains a relatively concentrated net amount of methyl donors.
  • methyl donors are present in the composition in a much higher amount than methyl donors.
  • the present composition preferably contains methyl donors and methyl acceptors in a ratio of at least 3:1, whereby the methyl donors are selected from the group consisting of L-serine, methionine, choline, phosphatidyl choline, betaine, dimethylglycine, sarcosine, methylated folates, S-adenosyl methionine, thymidine triphosphate, adenosine triphosphate and combinations thereof, and optionally methyl acceptors are present selected from the group consisting of L-glycine, ethanolamine, phosphatidyl ethanolamine, folate, ribose and combinations thereof.
  • compositions where the methyl donor is L- serine
  • Example 1 Complete tube feeding for enteral administration Protein: 17en%, digestible carbohydrates: 47 en%, lipids: 36 en%.
  • the composition contains, per 100 ml, 4.0 g casein, 0.2 g L-serine, 12.2 g maltodextrins, 3.9 g vegetable oils, 0.2 g lecithin, 0.1 g dimethylglycine, minerals and vitamins according to recommendations except folic acid (30 ⁇ g), vitamin B6 (0.2 mg), vitamin B 12 (0.5 ⁇ g).
  • the product contains, per 100 g powder, 94 g whey protein concentrate, 1 g creatine, 1 g L-serine, 1 g L-leucinecut 2 g flavors, 0.5 g xanthan gum, 0.3 g colorant, 0.1 g sucralose, 0.1 g citric acid.
  • Protein 12en%, digestible carbohydrates: 39 en%, lipids: 49 en%.
  • Powder which contains, per 100 ml after dissolving in with water according to prescription: Protein: whey 1.4 g, casein 0.9 g, L-serine 0.1 g; Carbohydrates: lactose 6.0 g, maltodextrins 1.8 g;
  • Lipids butter fat 1.3 g, mixture of marine oils 0.05 g, vegetable oils 2.4 g, lecithin 0.25 g.
  • vitamin B12 as hydroxycobalamine: 0.3 ⁇ g
  • Example 4 Product for persons suffering from pressure wounds Pudding comprising, per 100 g : Protein: 31en% (dairy 9.9 g, L-Arg 0.1 g, L-Ser 0.2 g)
  • Carbohydrates 49 en% (sucrose 9.4 g, lactose 4.2 g, saccharides from maltodextrins 2-3 g)
  • Lipids 20 en% (butter fat 1.0 g, algal oil 0.2 g, vegetable oils 1.8 g).
  • Example 5 Product for athletes wpc 80* (yielding 40 grams of whey protein) 50 grams whey protein hydrolysates 2 grams calcium caseinate 8 grams
  • * wpc 80 whey protein concentrate having an average protein content of about 80% on weight basis.
  • Example 6 Product for athletes to be dissolved in a liquid before consumption calcium caseinate 40 grams wpc 80* (yielding 8 grams of whey protein) 10 grams whey protein hydrolysates 2 grams
  • wpc 80 whey protein concentrate having an average protein content of about 80%) on weight basis.
  • Example 7 Product for anabolic purposes wpc 80* (yielding 40 grams of whey protein) 50 grams whey protein hydrolysates 2 grams calcium caseinate 8 grams L-leucine 2.8 grams
  • * wpc 80 whey protein concentrate having an average protein content of about 80% on weight basis.
  • Example 8 Product for improving lean body mass wpc 80* (yielding 30 grams of whey protein) 37.5 grams calcium caseinate 5 grams egg white protein 5 grams L-glutamine 5 grams
  • * wpc 80 whey protein concentrate having an average protein content of about 80% on weight basis.
  • Example 9 Liquid formula for complete nutrition of a person that is at risk or suffering from decubitus that comprises per 100 ml:
  • Liquid formula for perioperative use comprising per 100 ml:
  • Infant formula for premature infants that comprises per 100 ml

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
EP03760968A 2002-06-19 2003-06-19 Methode und zusammensetzung zur behandlung oder vorbeugung von abbaureaktionen oder zur stimulierung von aufbaureaktionen in säugetieren, die sich unter stress befinden Ceased EP1513419A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP16199313.4A EP3184107A1 (de) 2002-06-19 2003-06-19 Verfahren und zubereitung zur behandlung von metabolischem stress
EP03760968A EP1513419A2 (de) 2002-06-19 2003-06-19 Methode und zusammensetzung zur behandlung oder vorbeugung von abbaureaktionen oder zur stimulierung von aufbaureaktionen in säugetieren, die sich unter stress befinden
EP20100186325 EP2283835A3 (de) 2002-06-19 2003-06-19 Ernährungs- oder pharmazeutische Zusammensetzung zur Steigerung der Kapazität der Methylierungsreaktion in Organismen

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP02077434 2002-06-19
EP02077434 2002-06-19
US45253703P 2003-03-07 2003-03-07
US452537P 2003-03-07
EP03760968A EP1513419A2 (de) 2002-06-19 2003-06-19 Methode und zusammensetzung zur behandlung oder vorbeugung von abbaureaktionen oder zur stimulierung von aufbaureaktionen in säugetieren, die sich unter stress befinden
PCT/NL2003/000449 WO2004000042A2 (en) 2002-06-19 2003-06-19 Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP16199313.4A Division EP3184107A1 (de) 2002-06-19 2003-06-19 Verfahren und zubereitung zur behandlung von metabolischem stress

Publications (1)

Publication Number Publication Date
EP1513419A2 true EP1513419A2 (de) 2005-03-16

Family

ID=30001854

Family Applications (3)

Application Number Title Priority Date Filing Date
EP16199313.4A Withdrawn EP3184107A1 (de) 2002-06-19 2003-06-19 Verfahren und zubereitung zur behandlung von metabolischem stress
EP03760968A Ceased EP1513419A2 (de) 2002-06-19 2003-06-19 Methode und zusammensetzung zur behandlung oder vorbeugung von abbaureaktionen oder zur stimulierung von aufbaureaktionen in säugetieren, die sich unter stress befinden
EP20100186325 Ceased EP2283835A3 (de) 2002-06-19 2003-06-19 Ernährungs- oder pharmazeutische Zusammensetzung zur Steigerung der Kapazität der Methylierungsreaktion in Organismen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP16199313.4A Withdrawn EP3184107A1 (de) 2002-06-19 2003-06-19 Verfahren und zubereitung zur behandlung von metabolischem stress

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP20100186325 Ceased EP2283835A3 (de) 2002-06-19 2003-06-19 Ernährungs- oder pharmazeutische Zusammensetzung zur Steigerung der Kapazität der Methylierungsreaktion in Organismen

Country Status (7)

Country Link
EP (3) EP3184107A1 (de)
JP (1) JP2005529980A (de)
CN (1) CN100469361C (de)
AU (1) AU2003247225A1 (de)
BR (1) BRPI0311909A8 (de)
PL (1) PL375076A1 (de)
WO (1) WO2004000042A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19836339B4 (de) 1998-08-11 2011-12-22 N.V. Nutricia Kohlenhydratmischung
EP1597978A1 (de) 2004-05-17 2005-11-23 Nutricia N.V. Synergie von GOS und polyfruktose
US8252769B2 (en) 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
EP1723951A1 (de) * 2005-04-21 2006-11-22 N.V. Nutricia Nahrungsergänzungspräparat mit Oligosacchariden für eine Kategorie von HIV Patienten
EP1645276A1 (de) * 2004-10-08 2006-04-12 Wageningen Centre for Food Sciences Behandlung von neurodegenerativen Erkrankungen
CN101179954A (zh) * 2004-11-12 2008-05-14 荷兰纽迪希亚公司 用于快速减弱炎症反应的含有蛋白质和脂质的食品组合物
EP1680967A1 (de) * 2005-01-14 2006-07-19 Forum Media Productions SPRL Diätetische Zusammensetzungen auf Basis von löslichem Milchproteinisolat
WO2006099237A1 (en) * 2005-03-10 2006-09-21 Sciele Pharma, Inc. Nutritional preparations
RU2428056C2 (ru) 2005-04-27 2011-09-10 Н.В. Нютрисиа Питание с липидами и неперевариваемыми сахаридами
RU2422049C2 (ru) * 2005-08-02 2011-06-27 Альцхем Тростберг Гмбх Жидкая композиция, основанная на компоненте гуанидинуксусной кислоты
EP1774973A1 (de) * 2005-10-12 2007-04-18 Nutricia N.V. Leucinreiche Zusammentsetzung
JP2007209231A (ja) * 2006-02-08 2007-08-23 Japan Organo Co Ltd クレアチン含有食品組成物
US8835396B2 (en) * 2006-12-15 2014-09-16 Bioenergy, Inc. Method and compositions for improving pulmonary hypertension
DE102007004781A1 (de) 2007-01-31 2008-08-07 Alzchem Trostberg Gmbh Verwendung von Guanidinoessigsäure(-Salzen) zur Herstellung eines gesundheitsfördernden Mittels
ITMI20081405A1 (it) * 2008-07-29 2010-01-30 Velleja Res Srl Formulazioni orali istantanee, gelificanti a temperatura ambiente, utili per contrastare il deperimento organico e la sindrome depressiva connessi a cachessia, anoressia, malattia metabolica, malattia endocrina e disfagia
DE202013006354U1 (de) * 2013-07-15 2014-10-20 Marianne Brøndlund Stoffgemisch zur Behandlung von Koagulopathien
RU2761873C2 (ru) 2016-12-23 2021-12-13 Кэйо Юниверсити Композиции и способы для индукции cd8+ t-клеток
JP2019024389A (ja) * 2017-07-28 2019-02-21 株式会社明治 筋力向上用アミノ酸組成物
CN111655250A (zh) 2018-01-26 2020-09-11 味之素株式会社 伤害感受性疼痛的预防或改善用组合物
AU2019217041B2 (en) * 2018-02-09 2022-09-15 Keio University Compositions and methods for the induction of CD8+ T-cells
CN112689504A (zh) * 2018-06-20 2021-04-20 胺细拉健康公司 含有苦味氨基酸的治疗和保健组合物
CN110028570A (zh) * 2018-10-31 2019-07-19 华中科技大学 一种肌肉素的表达方法及其在代谢疾病中的应用
EP3873415A1 (de) 2018-11-02 2021-09-08 Unilever Global Ip Limited Bioenergetische nicotinsäureglycerinester, zusammensetzungen und verfahren zur verwendung davon
HUP2000298A1 (hu) * 2020-09-11 2022-03-28 Laszlo Gyulai Vírusfertõzés, elõnyösen SARS-COV-2 és IBV koronavírusok fertõzésének visszaszorítására alkalmazható táplálék-kiegészítõ vagy gyógyászati vagy gyógyszerkészítmény és formulálásuk
CN117545498A (zh) * 2021-05-14 2024-02-09 荷兰医疗食品有限公司 用于保持肌肉量的营养组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010033884A1 (en) * 2000-03-03 2001-10-25 F.G.A. Laboratories Flavourence Corporation Process of preserving food and food preservative

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB696405A (en) * 1950-12-15 1953-08-26 California Inst Res Found Improvements in or relating to preparations for muscular and nervous disorders and method of preparing the same
IL31992A (en) * 1968-05-08 1973-07-30 American Cyanamid Co Synthetic thyrocalcitonins and a method for their preparation
US3873722A (en) * 1974-05-31 1975-03-25 Nelson Res & Dev Method for treating schizophrenia
DE2832009A1 (de) * 1978-07-20 1980-01-31 Deutsches Krebsforsch Verwendung von sarkosin und sarkosinderivaten ls tumorhemmende wirksubstanzen
JPS56110617A (en) * 1980-02-08 1981-09-01 Ajinomoto Co Inc Nutrient composition for young child
US4461724A (en) * 1981-10-28 1984-07-24 Nippon Zoki Pharmaceutical Co., Ltd. Peptide compounds, a process for manufacturing them, pharmaceutical compositions containing them, and methods for treating ulcer and thrombus with them
US5665371A (en) * 1985-05-20 1997-09-09 Hoerrmann; Wilhelm Medicines which contain derivatives of proline or hydroxyproline
US5236899A (en) * 1987-11-16 1993-08-17 Merck & Co., Inc. 6-position cyclosporin a analogs as modifiers of cytotoxic drug resistance
US5026721A (en) * 1989-06-05 1991-06-25 Dudrick Stanley J Amino acid nutritional supplement and regimen for enhancing physical performance through sound nutrition
KR930006993B1 (ko) * 1989-10-06 1993-07-26 미쓰이 도오아쓰 가가쿠 가부시키가이샤 효소법에 의한 l-세린의 제조법
FR2675996B1 (fr) * 1991-04-30 1993-10-15 Georges Baritiu Compositions sanogenes dietetiques complexes.
CA2078019C (en) * 1991-09-13 2002-08-27 Siegbert Heinrich Bissbort Substance or composition and uses thereof
US5856148A (en) * 1991-12-12 1999-01-05 Wacker Chemie Gmbh Materials and methods for biosynthesis of serine and serine-related products
CA2183422A1 (en) * 1994-02-24 1995-08-31 Kiyoshi Mukai Analgesic activity enhancer
US6221836B1 (en) * 1996-07-26 2001-04-24 Paxton King Beale Composition of pyruvate and anabolic protein and method for increasing fat loss in a mammal
EP0891719A1 (de) * 1997-07-14 1999-01-20 N.V. Nutricia Narungszusammensetzungen mit Gehalt an Methionin
US6514973B1 (en) * 1998-10-30 2003-02-04 Merck Patent Geseilschaft Mit Beschrankter Haftung Compositions for the treatment and prevention of neurological and pathopsychological diseases
PT1062879E (pt) * 1999-06-26 2003-12-31 Braun Melsungen Ag Solucao aquosa para nutricao parenteral
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
ATE457726T1 (de) * 2002-06-19 2010-03-15 Nutricia Nv Nahrungs- oder pharmazeutische zusammensetzungen zur erhöhung der creatin-antwort von organismen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010033884A1 (en) * 2000-03-03 2001-10-25 F.G.A. Laboratories Flavourence Corporation Process of preserving food and food preservative

Also Published As

Publication number Publication date
BR0311909A (pt) 2005-04-05
JP2005529980A (ja) 2005-10-06
CN1674795A (zh) 2005-09-28
EP2283835A3 (de) 2011-12-28
BRPI0311909A8 (pt) 2018-02-06
CN100469361C (zh) 2009-03-18
WO2004000042A3 (en) 2004-05-06
AU2003247225A8 (en) 2004-01-06
EP3184107A1 (de) 2017-06-28
AU2003247225A1 (en) 2004-01-06
PL375076A1 (en) 2005-11-14
WO2004000042A2 (en) 2003-12-31
EP2283835A2 (de) 2011-02-16

Similar Documents

Publication Publication Date Title
EP1513419A2 (de) Methode und zusammensetzung zur behandlung oder vorbeugung von abbaureaktionen oder zur stimulierung von aufbaureaktionen in säugetieren, die sich unter stress befinden
US8703725B2 (en) Nutritional compositions
EP1455603B1 (de) Anregung der in-vivo synthese von proteinen mit zusammensetzungen enthaltend leucin
US7790209B2 (en) Total enteral nutritious composition
EP1536781B1 (de) Nahrungs- oder pharmazeutische zusammensetzungen zur erhöhung der creatin-antwort von organismen
US7375089B2 (en) Rehydration composition
JP5315996B2 (ja) 総合経腸栄養組成物
EP0891719A1 (de) Narungszusammensetzungen mit Gehalt an Methionin
JP2003532679A (ja) リボース及び葉酸を含有する栄養調合物及びその医学的使用
US8697679B2 (en) Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress
US20160021921A1 (en) Preterm infant nutritional compositions containing beta-hydroxy-beta-methylbutyric acid
US20090005320A1 (en) Compositions comprising amino acid bicarbonate and methods of use thereof
EP2986162A1 (de) Kalorienarmes säuglingsnährpräparat
ZA200501922B (en) Leucine-enriched nutritional compositions.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041215

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1074565

Country of ref document: HK

17Q First examination report despatched

Effective date: 20080313

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20111114

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1074565

Country of ref document: HK